GLP-1CultureThere’s No Good Way to Talk About Celebrities and Eating DisordersBy Kat TenbargeBusinessThe Great Peptide Cash Grab Has BegunBy Kate KnibbsBusinessJust About Anyone Can Sell You GLP-1s Online NowBy Kate KnibbsScienceI Was Scammed Buying GLP-1s Online. I’m Not AloneBy John SemleyScienceFDA Approves Eli Lilly’s GLP-1 PillBy Emily MullinScienceAI Digital Twins Are Helping People Manage Diabetes and ObesityBy Emily MullinScienceFDA Approves Pill Version of WegovyBy Emily MullinSciencePeople Are Already Taking This Unapproved New Weight-Loss DrugBy John SemleyScienceWeight-Loss Drug Zepbound Is Being Tested as a Treatment for Long CovidBy Emily MullinScienceEli Lilly’s Obesity Pill Shows Promising Weight Loss in New ResultsBy Emily MullinScienceEli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1sBy Emily MullinScienceA New Obesity Pill May Burn Fat Without Suppressing AppetiteBy Emily MullinScienceWhy Women With Type 2 Diabetes Are Diagnosed Later Than MenBy Lori YoumshajekianBusinessBlocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective DrugBy Kate KnibbsSciencePatients Are Left With Few Options as GLP-1 Copycats DisappearBy Emily Mullin and Kate KnibbsScienceDiabetes Is Rising in Africa. Could It Lead to New Breakthroughs?By David CoxBusinessEli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff DrugsBy Kate Knibbs and Emily MullinScienceThe Ozempic Shortage Is OverBy Kate Knibbs and Emily MullinScienceYour Love Life on OzempicBy Emily MullinThe Big StoryThe King of Ozempic Is Scared as HellBy Virginia HeffernanScienceThe Crackdown on Compounded GLP-1 Meds Has BegunBy Kate KnibbsScienceA Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t CelebratingBy Kate KnibbsScienceThe Benefits of Ozempic Are MultiplyingBy Emily MullinScienceThe Race for the Next OzempicBy Emily MullinMore Stories
